UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934
Filed by the Registrant x
Filed by a Party other than the Registrant
¨
Check the appropriate box:
| ¨ | Preliminary
Proxy Statement |
| ¨ | Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ¨ | Definitive
Proxy Statement |
| x | Definitive Additional Materials |
| ¨ | Soliciting
Material Pursuant to §240.14a-12 |
CHURCHILL CAPITAL
CORP VII
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement,
if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
| ¨ | Fee
paid previously with preliminary materials. |
| ¨ | Fee
computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and
0-11. |
Redemption Deadline for Churchill VII stockholders
extended until August 9, 2024
Stockholders may elect to redeem shares of Class
A Common Stock until 5:00 pm Eastern Time, August 9, 2024
NEW YORK August 5, 2024 – Churchill Capital Corp VII (“Churchill
VII”) (Nasdaq: CVII), a special purpose acquisition company, announced today that the deadline for Churchill VII stockholders
to elect redemption of their shares of class A common stock of Churchill VII (“Class A Common Stock”) in connection
with the proposed business combination between CorpAcq Holdings Limited (“CorpAcq”), and Churchill VII (the “Business
Combination”) is extended until 5:00 P.M., Eastern Time on August 9, 2024. The redemption deadline is being extended so that
stockholders will have sufficient time to evaluate certain additional disclosure in respect of the Business Combination furnished on
Form 8-K and filed on Schedule 14A by Churchill VII on August 5, 2025 (the “Form 8-K”). Churchill VII’s stockholders
are advised to read the Form 8-K.
Any request for redemption, once made by a holder of Class A
Common Stock, may be withdrawn at any time up to the time the vote is taken with respect to the Business Combination at the special
meeting of Churchill VII’s stockholders (the “Stockholder Special Meeting”) to be reconvened on August 12,
2024 at 10:00 A.M., Eastern Time. If a stockholder has previously submitted a request to redeem its shares Class A Common Stock in
connection with the Stockholder Special Meeting and would like to reverse such request, such stockholder may make such request by
contacting the Churchill VII’s transfer agent at the following address:
Continental Stock Transfer & Trust Company
One State Street Plaza, 30th Floor
New York, NY 10004
Attn: SPAC Redemption Team
Email: spacredemptions@continentalstock.com
Churchill VII Stockholder and Warrant Holder Meetings
On August 12, 2024, Churchill VII will reconvene the previously
adjourned Stockholder Special Meeting at 10:00 A.M., Eastern Time, to consider and vote on, among other proposals, a proposal to
adopt the merger agreement in respect of the Business Combination and approve the Business Combination and the previously adjourned
meeting of Churchill VII’s public warrantholders at 10:30 A.M., Eastern Time, to consider and vote on, among other proposals, a
proposal to amend the existing warrant agreement that governs all of Churchill VII’s outstanding warrants.
Churchill VII stockholders and warrant holders who need assistance
voting, have questions regarding the meetings, or would like to request documents may contact Churchill VII’s proxy solicitor, Morrow
Sodali LLC, by calling (800) 662-5200 (toll-free) or banks and brokers may call (203) 658-9400, or by emailing CVII.info@investor.morrowsodali.com.
About CorpAcq Holdings Limited
CorpAcq is a corporate compounder founded in 2006 with deep commercial
experience and has established a diversified portfolio of 42 subsidiaries (as of December 31, 2023) across multiple large industries.
CorpAcq has a track record of unlocking business potential and long-term growth for small and medium-sized enterprises through its established
M&A playbook and decentralized operational approach. CorpAcq’s executive team develops close relationships with their subsidiaries’
management to support them with financial and strategic expertise while allowing them to retain independence to continue to operate their
businesses successfully. CorpAcq is headquartered in the United Kingdom.
About Churchill Capital Corp VII
Churchill VII was formed for the purpose of effecting a merger, capital
stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
Additional Information and Where to Find It
This communication does not contain all the information that should
be considered concerning the business combination between CorpAcq and Churchill VII (“Business Combination”) and the
other transactions contemplated thereby (the “Transactions”) and is not intended to form the basis of any investment
decision or any other decision in respect of the Transactions.
A post-effective amendment to the Registration Statement on Form F-4
filed by CorpAcq Group Plc in respect of the Business Combination (the “Post-Effective Amendment”) was made effective
by the U.S. Securities and Exchange Commission (the “SEC”) on June 20, 2024 and includes the proxy statement/prospectus
(the “Proxy Statement”) which was made available to Churchill VII’s stockholders and public warrant holders
in connection with Churchill VII’s solicitation for proxies for the vote by Churchill VII’s stockholders and public warrant
holders in connection with the Transactions and other matters described in the Proxy Statement, as well as the prospectus relating to
the offer and sale of securities to be issued by CorpAcq Group Plc to Churchill VII’s stockholders and public warrant holders in
connection with the completion of the Transactions.
Before making any voting or other investment decisions, Churchill VII’s
stockholders and public warrant holders and other interested persons are advised to read the Post-Effective Amendment and the Proxy Statement,
in connection with Churchill VII’s solicitation of proxies for its Stockholder Special Meeting and its Warrant Holder Meeting, as
well as the Form 8-K and other documents filed with the SEC by Churchill VII or CorpAcq Group Plc in connection with the Transactions
and any amendments thereto, as these documents contain important information about CorpAcq, CorpAcq Group Plc, Churchill VII and the Transactions.
Churchill VII first mailed the Proxy Statement and other relevant documents
to its stockholders and public warrant holders as of the Record Date on or about June 20, 2024. Stockholders and public warrant holders
may also obtain a copy of the Post-Effective Amendment and the Proxy Statement, as well as other documents filed by Churchill VII or CorpAcq
Group Plc with the SEC, without charge, at the SEC’s website located at www.sec.gov or by directing a written request to Churchill
Capital Corp VII at 640 Fifth Avenue, 12th Floor, New York, NY 10019.
Forward-Looking Statements
This communication includes “forward-looking statements”
within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by the use of words such as “estimate,” “plan, ” “project, ” “forecast,
” “intend, ” “will, ” “expect, ” “anticipate, ” “believe, ” “seek, “
“target, ” “continue,” “could, ” “may,” “might,” “possible,” “potential,”
“predict” or other similar expressions that predict or indicate future events or trends or that are not statements of historical
matters. Churchill VII and CorpAcq have based the forward-looking statements on its current expectations about future performance, timing
and events. The forward-looking statements in this communication include, but are not limited to, statements regarding estimates and the
anticipated timing for the Business Combination to close. The forward-looking statements are based on various assumptions, whether or
not identified in this communication, and on the current expectations of CorpAcq’s and Churchill VII’s respective management
teams and are not predictions of actual timing and/or performance. Nothing in this communication should be regarded as a representation
by any person that the forward-looking statements set forth herein will be achieved. The forward-looking statements are provided for illustrative
purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction or
a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may materially
differ from assumptions. Many actual events and circumstances are beyond the control of Churchill VII and CorpAcq. The forward-looking
statements are subject to known and unknown risks, uncertainties and assumptions about Churchill VII and CorpAcq that may cause the timing
and/or performance indicated in this communication to be materially different from any actual future results, levels of activity, performance
or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include changes in domestic and
foreign business changes in the competitive environment in which CorpAcq operates; CorpAcq’s ability to manage its growth prospects,
meet its operational and financial targets, and execute its strategy; the impact of any economic disruptions, decreased market demand
and other macroeconomic factors, including the effect of a global pandemic, to CorpAcq’s business, projected results of operations,
financial performance or other financial metrics; CorpAcq’s reliance on its senior management team and key employees; risks related
to liquidity, capital resources and capital expenditures; failure to comply with applicable laws and regulations or changes in the regulatory
environment in which CorpAcq operates; the outcome of any potential litigation, government and regulatory proceedings, investigations,
actions (including any potential U.S. or U.K. government shutdowns) and inquiries that Churchill VII or CorpAcq may face; assumptions
or analyses used for CorpAcq’s forecasts proving to be incorrect and causing its actual operating and financial results to be significantly
below its forecasts; CorpAcq failing to maintain its current level of acquisitions or an acquisition not occurring as planned and negatively
affecting operating results; the inability of the parties to successfully or timely consummate the Transactions, including the risk that
any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect
CorpAcq Group Plc, which will be the combined company after the Transactions, or the expected benefits of the Transactions or that the
approval of the stockholders of Churchill VII is not obtained; the risk that stockholders of Churchill VII could elect to have their shares
redeemed by Churchill VII, leading to either Churchill VII failing to satisfy continued listing requirements for Nasdaq Global Market
or Churchill VII having insufficient cash to complete the Transactions; that CorpAcq or Churchill VII will enter into financing arrangements
in support of the Transactions; the outcome of any legal proceedings that may be instituted against CorpAcq or Churchill VII; changes
in applicable laws or regulations; the ability of Churchill VII or CorpAcq Group Plc to issue equity or equity linked securities in connection
with the Transactions or in the future; the impact of certain geopolitical events, including wars in Ukraine and the surrounding region
and the Middle East; the impact of a current or future pandemic on CorpAcq, CCVII, or CorpAcq Group’s projected results of operations,
financial performance or other financial metrics, or on any of the foregoing risks; those factors discussed in under the heading “Risk
Factors” in the Proxy Statement, as may be further amended from time to time, and other documents filed, or to be filed, with the
SEC by Churchill VII or CorpAcq Group Plc. If any of these risks materialize or CorpAcq’s, CorpAcq Group Plc’s or Churchill
VII’s assumptions prove incorrect, actual timing and/or performance could differ materially from the timing and/or performance implied
by the forward-looking statements. There may be additional risks that CorpAcq, CorpAcq Group Plc nor Churchill VII presently know or that
CorpAcq, CorpAcq Group Plc and Churchill VII currently believe are immaterial that could also cause actual timing and/or performance to
differ materially from those contained in the forward-looking statements. In addition, the forward-looking statements reflect CorpAcq’s,
CorpAcq Group Plc’s and Churchill VII’s expectations and views as of the date of this communication. CorpAcq, CorpAcq Group
Plc’s and Churchill VII anticipate that subsequent events and developments will cause CorpAcq’s, CorpAcq Group Plc’s
and Churchill VII’s assessments to change. However, while CorpAcq, CorpAcq Group Plc and Churchill VII may elect to update these
forward-looking statements at some point in the future, CorpAcq, CorpAcq Group Plc and Churchill VII specifically disclaim any obligation
to do so. The forward-looking statements should not be relied upon as representing CorpAcq, CorpAcq Group Plc and Churchill VII’s
assessments as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking
statements. An investment in CorpAcq, CorpAcq Group Plc or Churchill VII is not an investment in any of CorpAcq’s, CorpAcq Group
Plc’s or Churchill VII’s founders’ or sponsors’ past investments or companies or any funds affiliated with any
of the foregoing.
No Offer or Solicitation
This communication does not constitute an offer to sell or the solicitation
of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction
in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such
jurisdiction. This communication is not, and under no circumstances is to be construed as, a proxy statement or solicitation of a proxy,
a prospectus, an advertisement or a public offering of the securities described herein in the United States or any other jurisdiction.
No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933,
as amended, or exemptions therefrom. INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED BY THE SEC OR ANY OTHER REGULATORY
AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED
HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
Participants in the Solicitation
CorpAcq, CorpAcq Group Plc, Churchill VII, Churchill Sponsor VII LLC
and their respective directors and executive officers may be deemed participants in the solicitation of proxies from Churchill VII’s
stockholders and public warrant holders with respect to the Transactions. A list of the names of Churchill VII’s directors and executive
officers and a description of their interests in Churchill VII is set forth in certain filings with the SEC, including (but not limited
to) the following: (1) the Definitive Proxy Statement (https://www.sec.gov/Archives/edgar/data/1828248/000110465924073479/tm2417668-1_defm14a.htm)
(and specifically, the following sections: “Risk Factors-Risks Related to Churchill and the Business Combination”; “Information
Related to Churchill-Management, Directors and Executive Officers”; “The Business Combination-Interests of Certain Persons in
the Business Combination; Interests of the Churchill Initial Stockholders and Churchill’s Directors and Officers”; “Beneficial
Ownership of Churchill Securities” and “Certain Relationships and Related Person Transactions-Churchill Relationships and Related
Person Transactions”), (2) the Form 10-K filed by Churchill VII with the SEC on April 1, 2024 (https://www.sec.gov/Archives/edgar/data/1828248/000141057824000414/cvii-20231231x10k.htm)
(and specifically, the following sections: “Item 1A. Risk Factors”; “Item 10. Directors, Executive Officers and Corporate
Governance”; “Item 11. Executive Compensation”; “Item 12. Security Ownership of Certain Beneficial Owners and Management
and Related Stockholder Matters”; “Item 13. Certain Relationships and Related Transactions, and Director Independence”
and “Item 15. Exhibits and Financial Statement Schedules-Note 5. Related Party Transactions”), (3) the Form 10-Qs filed by Churchill
VII with the SEC on May 10, 2023 (https://www.sec.gov/Archives/edgar/data/1828248/000141057823000982/cvii-20230331x10q.htm), August 9,
2023 (https://www.sec.gov/Archives/edgar/data/1828248/000141057823001631/cvii-20230630x10q.htm), November 9, 2023 (https://www.sec.gov/ix?doc=/Archives/edgar/data/1828248/000141057823002315/cvii-20230930x10q.htm)
and May 3, 2024 (https://www.sec.gov/Archives/edgar/data/1828248/000141057824000589/cvii-20240331x10q.htm) (and specifically, the discussion
under “Item 1. Financial Statements-Note 5. Related Party Transactions” section in each such Form 10-Qs, respectively), (4)
the Form 8-K filed by Churchill VII with the SEC on August 7, 2023 (https://www.sec.gov/Archives/edgar/data/1828248/000110465923087944/tm2322945d1_8k.htm)
(and specifically, the disclosure under “Item 1.01 Entry Into a Material Definitive Agreement-Amended and Restated Sponsor Agreement”),
(5) the Form 8-K filed by Churchill VII with the SEC on December 26, 2023 (https://www.sec.gov/ix?doc=/Archives/edgar/data/1828248/000110465923129191/tm2333487d1_8k.htm)
(and specifically, the disclosure under “Item 1.01 Entry Into a Material Definitive Agreement-Consent and Merger Agreement Amendment”),
(6) the SCHEDULE 14A filed by Churchill VII with the SEC on January 22, 2024 (https://www.sec.gov/Archives/edgar/data/1828248/000110465924005304/tm2333205-2_def14a.htm)
(and specifically, the following sections: “The Business Combination-Interests of Certain Persons in the Business Combination”
and “Beneficial Ownership of Churchill Securities”), and (7) other documents that may be filed with the SEC from time to time
in connection with the Transactions, each of which are available free of charge at the SEC’s website located at www.sec.gov, or
by directing a written request to Churchill Capital Corp VII at 640 Fifth Avenue, 12th Floor, New York, NY 10019.
Investor Relations Contact:
Email: CorpAcqIR@icrinc.com
Media Relations Contact:
Michael Landau
Gladstone Place Partners
(212) 230-5930
Churchill Capital Corp VII (NYSE:CVII)
Historical Stock Chart
Von Okt 2024 bis Nov 2024
Churchill Capital Corp VII (NYSE:CVII)
Historical Stock Chart
Von Nov 2023 bis Nov 2024
